OCUMENSION THERAPEUTICS |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.8 HKD | -2.02% |
|
-2.58% | +1.80% |
| Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
| Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,433 | 9,507 | 5,967 | 4,193 | 4,456 | - | - |
| Enterprise Value (EV) 1 | 11,382 | 7,733 | 4,682 | 4,193 | 3,694 | 3,750 | 3,607 |
| P/E ratio | - | -33.2 x | -13.5 x | -10.3 x | -17.8 x | -85.7 x | 21.4 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1,026 x | 169 x | 37.5 x | 17 x | 10.2 x | 5.57 x | 3.41 x |
| EV / Revenue | 869 x | 138 x | 29.5 x | 17 x | 8.45 x | 4.69 x | 2.76 x |
| EV / EBITDA | -25.5 x | -20.1 x | -10.4 x | -10.7 x | -24.5 x | 973 x | 14.6 x |
| EV / FCF | - | -8.97 x | -14.8 x | - | 16.9 x | 39.5 x | 52.3 x |
| FCF Yield | - | -11.1% | -6.76% | - | 5.9% | 2.53% | 1.91% |
| Price to Book | 5.37 x | 2.79 x | 2.17 x | - | 1.65 x | 1.72 x | 1.65 x |
| Nbr of stocks (in thousands) | 591,140 | 666,743 | 688,737 | 690,665 | 693,655 | - | - |
| Reference price 2 | 22.72 | 14.26 | 8.664 | 6.072 | 6.424 | 6.424 | 6.424 |
| Announcement Date | 3/19/21 | 3/25/22 | 3/30/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.1 | 56.15 | 159 | 246.4 | 437.1 | 800.3 | 1,307 |
| EBITDA 1 | -447.1 | -383.9 | -452.3 | -393.1 | -150.9 | 3.853 | 247.7 |
| EBIT 1 | -451.7 | -385.9 | -455.9 | -402.1 | -250.5 | -91.81 | 114.9 |
| Operating Margin | -3,449.28% | -687.36% | -286.78% | -163.23% | -57.3% | -11.47% | 8.79% |
| Earnings before Tax (EBT) 1 | - | -260 | -402.2 | -379.5 | -250.4 | -53.51 | 240.9 |
| Net income 1 | - | -260 | -402.6 | -379.8 | -250.9 | -3.016 | 204.8 |
| Net margin | - | -463.06% | -253.3% | -154.15% | -57.41% | -0.38% | 15.67% |
| EPS 2 | - | -0.4300 | -0.6400 | -0.5900 | -0.3600 | -0.0750 | 0.3000 |
| Free Cash Flow 1 | - | -861.7 | -316.5 | - | 218 | 95 | 69 |
| FCF margin | - | -1,534.67% | -199.09% | - | 49.87% | 11.87% | 5.28% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 2,465.43% | 27.85% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 33.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/19/21 | 3/25/22 | 3/30/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 11.14 | 20.8 | 35.34 | 54.54 | 104.4 | 103.7 | 142.7 | 169.5 | 259.7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | -179.7 | -206.2 | -218.5 | -237.4 | -224.9 | -177.3 | -152.3 | -132.8 |
| Operating Margin | - | - | -863.94% | -583.43% | -400.68% | -227.3% | -216.86% | -124.26% | -89.82% | -51.12% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | -1,742 | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS | -27.00 | - | - | - | -0.3100 | -0.3300 | -0.3200 | -0.2700 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/26/20 | 3/19/21 | 8/20/21 | 3/25/22 | 8/26/22 | 3/30/23 | 8/24/23 | 3/21/24 | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 2,052 | 1,774 | 1,285 | - | 762 | 706 | 849 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -862 | -316 | - | 218 | 95 | 69 |
| ROE (net income / shareholders' equity) | -128% | -9.27% | -13.7% | - | -7.84% | -4.31% | 3.75% |
| ROA (Net income/ Total Assets) | - | -8.77% | -12.6% | - | -7% | -2.9% | - |
| Assets 1 | - | 2,965 | 3,187 | - | 3,585 | 104 | - |
| Book Value Per Share 2 | 4.230 | 5.120 | 3.990 | - | 3.900 | 3.740 | 3.900 |
| Cash Flow per Share 2 | - | -0.3200 | -0.3200 | - | 0.4200 | 0.3000 | - |
| Capex 1 | - | 665 | 116 | - | 75 | 114 | 167 |
| Capex / Sales | - | 1,184.07% | 72.86% | - | 17.16% | 14.24% | 12.78% |
| Announcement Date | 3/19/21 | 3/25/22 | 3/30/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.424
CNY
Average target price
8.653
CNY
Spread / Average Target
+34.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.80% | 617M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +13.91% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 1477 Stock
- Financials Ocumension Therapeutics
